These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16679727)

  • 1. Probenecid: its chromatographic determination, plasma protein binding, and in vivo pharmacokinetics in dogs.
    Kakizaki T; Yokoyama Y; Natsuhori M; Karasawa A; Kubo S; Yamada N; Ito N
    J Vet Med Sci; 2006 Apr; 68(4):361-5. PubMed ID: 16679727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs.
    Kakizaki T; Yokoyama Y; Natsuhori M; Yamada N; Hashimoto M; Sato K; Ito N; Daniel GB
    J Vet Pharmacol Ther; 2005 Dec; 28(6):559-64. PubMed ID: 16343289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enantiomer-enantiomer interaction of a uricosuric antihypertensive diuretic (DBCA) in renal tubular secretion and stereoselective inhibition by probenecid in the cynomolgus monkey.
    Nakano M; Higaki K; Kawahara S
    Xenobiotica; 1993 May; 23(5):525-36. PubMed ID: 8342300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares.
    Donecker JM; Sams RA; Ashcraft SM
    Am J Vet Res; 1986 Jan; 47(1):89-95. PubMed ID: 3946913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study.
    Baber N; Halliday L; Sibeon R; Littler T; Orme ML
    Clin Pharmacol Ther; 1978 Sep; 24(3):298-307. PubMed ID: 688724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the pharmacokinetics of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, in rats and dogs.
    Jinno F; Takeuchi T; Tagawa Y; Kondo T; Itoh T; Asahi S
    Drug Metab Dispos; 2012 Apr; 40(4):648-54. PubMed ID: 22203697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic model for the renal clearance of iodopyracet and the interaction with probenecid in the dog.
    Russel FG; Wouterse AC; Van Ginneken CA
    Biopharm Drug Dispos; 1989; 10(2):137-52. PubMed ID: 2706315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-linear elimination and protein binding of probenecid.
    Emanuelsson BM; Beermann B; Paalzow LK
    Eur J Clin Pharmacol; 1987; 32(4):395-401. PubMed ID: 3609117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid.
    Rao GS; Ramesh S; Ahmad AH; Tripathi HC; Sharma LD; Malik JK
    Vet J; 2002 Jan; 163(1):85-93. PubMed ID: 11749141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
    Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP
    Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent pharmacokinetics of probenecid in the rat.
    Emanuelsson BM; Paalzow LK
    Biopharm Drug Dispos; 1988; 9(1):59-70. PubMed ID: 3342285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal handling of fleroxacin in rabbits, dogs, and humans.
    Shiba K; Saito A; Shimada J; Hori S; Kaji M; Miyahara T; Kusajima H; Kaneko S; Saito S; Ooie T
    Antimicrob Agents Chemother; 1990 Jan; 34(1):58-64. PubMed ID: 2109576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of probenecid.
    Cunningham RF; Israili ZH; Dayton PG
    Clin Pharmacokinet; 1981; 6(2):135-51. PubMed ID: 7011657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study.
    Vree TB; Van Ewijk-Beneken Kolmer EW; Wuis EW; Hekster YA
    Pharm Weekbl Sci; 1992 Oct; 14(5):325-31. PubMed ID: 1437517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients.
    Massarella JW; Nazareno LA; Passe S; Min B
    Pharm Res; 1996 Mar; 13(3):449-52. PubMed ID: 8692740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical determination and pharmacokinetics of robenacoxib in the dog.
    Jung M; Lees P; Seewald W; King JN
    J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of probenecid following oral doses to human volunteers.
    Selen A; Amidon GL; Welling PG
    J Pharm Sci; 1982 Nov; 71(11):1238-42. PubMed ID: 7175716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment.
    Noormohamed FH; McNabb WR; Dixey JJ; Lant AF
    J Pharmacol Exp Ther; 1990 Sep; 254(3):992-9. PubMed ID: 2395126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.
    Baldwin JR; Lewis RC; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK
    Biopharm Drug Dispos; 1996 Aug; 17(6):541-50. PubMed ID: 8866044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.
    Landersdorfer CB; Kirkpatrick CM; Kinzig M; Bulitta JB; Holzgrabe U; Jaehde U; Reiter A; Naber KG; Rodamer M; Sörgel F
    Br J Clin Pharmacol; 2010 Feb; 69(2):167-78. PubMed ID: 20233180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.